Serbian Society of Surgical Oncology

14/03/2024

❗️Do you know there is still time to apply for the ESSO-EYSAC Surgical Anatomy Course on Pancreatic Cancer, which will be held
👉on 23-24 April, 2024
👉in Leiden University Medical Center, Leiden, NL
🩺This course is a great opportunity to gain some more hands-on experience on surgical anatomy and operative techniques combined with an update on the current concepts of treatment of pancreatic cancer
🫶 You can find out more here: https://www.essoweb.org/courses/esso-eysac-surgical-anatomy-course-on-pancreatic-cance2024/
🫶🧑‍⚕️👩‍⚕️👨‍⚕️🫶

29/11/2023

- Don’t miss!‼️

The EYSAC - ESSO Young Surgeons and Alumni Club was created with the aim to help junior surgeons and surgeons-in-training to play an active role in the future of surgical oncology. By connecting them, and creating a pathway for learning & collaborative research, ESSO has enabled young surgeons worldwide to contribute to the mission & vision of ESSO to .

This will cover wide range of topics of interest for and surgical residents, emphasizing the importance of being involved in , the necessity for scientific and professional with peers and senior mentors, the possibilities for in certified European cancer center, availability of certifications through and in oncology, and pointing out all the long-term benefits of and fellowships in surgical oncology.

All speakers at the session are in surgical oncology, members of EYSAC , EYSAC and various ESSO , and will try to share their own pathways and experiences within ESSO and EYSAC.

Join us!🔜

22/11/2023

‼️🚨

💡💡💡💡💡
Dear colleagues,

We are delighted to extend a special invitation for one of the 60th Oncology Congress Gynecology sessions, dedicated to Ovarian cancer, with our expert prim. dr sc. med. dr Ljiljana Stamatovic as a moderator.

➡️ Advanced epithelial ovarian cancer is associated with poor prognosis, as most patients experience relapse following the first line multimodal treatment. Once the disease relapses, it is largely incurable. First-line treatment for advanced ovarian cancer is the optimal setting to achieve a potential cure.

➡️ Treatment of ovarian cancer has traditionally been a combination of chemotherapy and surgery, primarily with surgical staging of affected tissue, tumor debulking surgery optimally to R0 resection, and subsequent chemotherapy. It has also been shown that initial neoadjuvant chemotherapy is a appropriate option for patients who are estimated not to be suitable for optimal primary surgery.

➡️ Genetic testing for gene mutations that affect treatment is recommended for all women with epithelial ovarian cancer. Maintenance therapy with poly ADP-ribose polymerase inhibitors, bevacizumab, and/or drugs targeting homologous recombination deficiency has become the standard of care in the treatment of ovarian cancer.

Full Scientific Program link ⬇️:
http://www.oncology.rs/wp-content/themes/onkology/public/media/programs/program.pdf

Registration available at ⬇️:
http://www.astakos.com/registration-kanceroloska-nedelja/

‼️Set your reminder on: November 30, 2023, 17:40-18:25

19/11/2023

14/09/2023

Dear friends ad colleagues,

EYSAC - ESSO Young Surgeons and Alumni Club in collaboration with the European-African Hepato-Pancreato-Biliary Association (E-AHPBA) are currently launching an online survey about the assessment and management of pancreatic neuroendocrine tumours (pNET) across European, and African countries and beyond.

If you fulfil the following requirements, please take your time and support our survey:
• Surgical treatment (consultation or operative) of pancreatic neuroendocrine tumours (pNET)
• Can Speak/Read English
• 7-10 minutes of time

The link to the survey is:
https://redcap.link/pNET-survey

Thank you for your participation and please share this invitation with your colleagues.

This survey is conducted to assess the current status of surgical management of pancreatic neuroendocrine tumours (pNET) & pancreatic neuroendocrine carcinomas (pNECs). Your information and opinion are important and will be helpful to improve the quality of pNET management within Africa & Europe.

10/07/2023

Global Hub, as an international collaborative working group for breast diseases, is studying the variance of practice for locally advanced breast cancer. If you are a breast specialist, please answer the below survey and spread it to your nearby networks.
Thank you very much for your time!

Global Breast Hub is a non-profit organisation set up to promote, standardise and advance safe and effective breast care around the globe. We will be grateful if you could spare 10 minutes to fill out this short online survey to analyse the variability in management of locally advanced breast cancer...